相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis
Tianshu Ren et al.
DRUG SAFETY (2021)
Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies
Dan Aderka et al.
LANCET ONCOLOGY (2019)
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer The ACHIEVE Phase 3 Randomized Clinical Trial
Takayuki Yoshino et al.
JAMA ONCOLOGY (2019)
aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
Yoshihiko Fujita et al.
ONCOLOGIST (2019)
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumabas First-line Chemotherapy in Metastatic Colorectal Cancer
Aparna R. Parikh et al.
CLINICAL CANCER RESEARCH (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)
Goro Nakayama et al.
ONCOLOGIST (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
Y. Yamada et al.
ANNALS OF ONCOLOGY (2018)
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
Alfredo Carrato et al.
EUROPEAN JOURNAL OF CANCER (2017)
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
K. Yamazaki et al.
ANNALS OF ONCOLOGY (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study
Chieh-Lin Jerry Teng et al.
PLOS ONE (2015)
Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study
Norbert Marschner et al.
CLINICAL EPIDEMIOLOGY (2015)
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)
G. Folprecht et al.
ANNALS OF ONCOLOGY (2014)
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
W. Schmiegel et al.
ANNALS OF ONCOLOGY (2013)
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
Yasuhide Yamada et al.
LANCET ONCOLOGY (2013)
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
Yong Sang Hong et al.
LANCET ONCOLOGY (2012)
Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104-A Randomized Trial of the German AIO CRC Study Group
Nicolas Moosmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study
G. Rosati et al.
ANNALS OF ONCOLOGY (2010)
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro et al.
LANCET ONCOLOGY (2010)
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
Janja Ocvirk et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Chemotherapy Treatments for Metastatic Colorectal Cancer: Is Evidence-Based Medicine in Practice?
Kathryn M. Field et al.
JOURNAL OF ONCOLOGY PRACTICE (2008)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis
Vassilis Golfinopoulos et al.
LANCET ONCOLOGY (2007)
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
Matthew T. Seymour et al.
LANCET (2007)
A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer
J. Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study
E. Bajetta et al.
BRITISH JOURNAL OF CANCER (2007)
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis
Kent R. Johnson et al.
LANCET ONCOLOGY (2006)
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American intergroup trial
Richard M. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer
J Feliu et al.
BRITISH JOURNAL OF CANCER (2005)
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
G Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
HP Kalofonos et al.
ANNALS OF ONCOLOGY (2005)
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial
P Comella et al.
ANNALS OF ONCOLOGY (2005)
Anti-angiogenic effects of SN38 (active metabolite of irinotecan):: inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells
H Kamiyama et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin - Results from Intergroup Trial N09741
T Delaunoit et al.
CANCER (2004)
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
RM Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)